Alzamend Neuro Inc (ALZN) reported a Q1 2025 nett loss of $0.974 million with no disclosed revenue in the period, underscoring the company’s ongoing transition from a developmental-stage biotech to a revenue-generation timeline dominated by clinical milestones rather than near-term sales. The quarter shows a controlled but meaningful burn driven mainly by research and development and general & administrative expenses, coupled with a modest EBITDA deterioration that remains negative at approximately $(0.95) million. Cash burn from operations stood at roughly $(1.06) million, while financing activity provided an inflow of about $1.96 million from common stock issuances, resulting in ending cash of $1.19 million. The balance sheet remains fragile: total assets of about $1.67 million against liabilities of $2.88 million and negative stockholders’ equity of approximately $(1.21) million, with liquidity ratios placing ALZN in a precarious near-term liquidity position (current/quick ratio ~0.49; cash ratio ~0.41).
From a strategic perspective, ALZN continues to advance AL001 (Phase II) and AL002 (preclinical), but the lack of revenue and the dependence on ongoing capital raises heighten earnings risk until pivotal clinical data are disclosed or strategic partnerships are formed. Management commentary from the earnings call is not included in the dataset, so the narrative is reconstructed from the 10-Q figures and company filings. The investment implication remains a high‑risk, high‑potential story: milestones around AL001 readouts or licensing partnerships could unlock significant upside, but financing-dependent liquidity creates substantial dilution risk and near-term uncertainty.